Moderna, Inc. — Form 8-K Summary
Reporting context: Current report dated September 30, 2026, covering executive appointments and a retirement. This filing does not report quarterly or annual financial results.
Business and executive changes
- Moderna appointed Juan Andres Chief Operating Officer, effective October 5, 2026. The newly created role is intended to support the company’s increasing scale and diversification. He will report to CEO Stephane Bancel and join the Executive Committee.
- Andres previously held Moderna roles from 2018 to 2023, including Chief Technical Operations and Quality Officer, and led manufacturing capability expansion, including for the COVID-19 vaccine.
- Jerh Collins, Ph.D., the current Chief Technical Operations and Quality Officer, will retire. The filing does not state a retirement date.
Compensation and financial information
- Andres’s initial annual base salary is $800,000. He is eligible for an annual cash bonus with a target of 90% of base salary, including a prorated 2026 bonus. Payout depends on performance goals and is determined at the Compensation and Talent Committee’s discretion.
- He is eligible for a $5 million new-hire equity award, subject to the company’s equity grant policy, with four-year vesting. He may choose a mix of non-qualified stock options and restricted stock units; no more than 75% of the award’s value may be in restricted stock units.
- Future annual equity awards are subject to Compensation Committee approval. The stated target value is $4 million to $5 million, subject to adjustment.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating performance metrics.
Outlook, conditions, and notable items
The filing includes no financial guidance or business outlook. Compensation amounts and eligibility are described in the 8-K; the offer letter is to be filed with a future periodic report. Andres will participate in the company’s Executive Severance Plan and has entered into an indemnification agreement and an employee confidentiality, assignment, nonsolicitation, and noncompetition agreement.
Investor facts to verify
- Review the offer letter when filed, including the equity award’s form, grant timing, and applicable terms.
- Confirm the effective transition date and any further details concerning Collins’s retirement.
- Monitor subsequent disclosures for committee decisions on bonus performance and future annual equity awards.